Teva Pharmaceutical Industries Ltd. (TEVA)

Oncology Corporate Profile

Stock Performance

33.0300
0.0000

HQ Location

1090 Horsham Rd.
North Wales, PA 19454

Company Description

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.

Website: http://www.tevapharm.com/

Brand Generic Indication
Actiq??fentanyl citrateACTIQ is an opioid analgesic indicated only for management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Bendeka_?bendamustine hydrochlorideBendamustine hydrochloride is an alkylating drug indicated for treatment of patients with:



_??Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.



_??Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Fentora??fentanyl buccalFENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who

are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant

are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of

transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic

dose of another opioid daily for a week or longer.

This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation and death could occur

at any dose in patients not on a chronic regimen of opioids. For this reason, FENTORA is contraindicated in the management of

acute or postoperative pain.

FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who

are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

Synribo_?omacetaxine mepesuccinateSYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO.
Tevagrastim??tbo_?_filgrastimTevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile

neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.



Tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).



In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an

absolute neutrophil count (ANC) of ? 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Tevagrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.



Tevagrastim is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x

109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Treanda??bendamustine hydrochlorideChronic Lymphocytic Leukemia (CLL)

TREANDA for Injection is an alkylating drug indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.



Non-Hodgkin_?_s Lymphoma (NHL)

TREANDA for Injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin_?_s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Trisenox??arsenic trioxideTRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the translocation or PML/RAR-alpha gene expression.

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
custirsen / TV-1011 (OGX-011)clusterin inhibitor1st line metastatic castrate-resistant Prostate cancer (CRPC)IIIOncogenex
custirsen / TV-1011 (OGX-011)clusterin inhibitor1st line metastatic Non Small Cell Lung Cancer (NSCLC)IIIOncogenex
custirsen (+ cabazitaxel) / TV-1011 (OGX-011)clusterin inhibitor2nd line metastatic castrate-resistant prostate cancer (CRPC)IIIOncogenex
Unnamedpeg-GCSFSupportive CareIII
Rituxan_ / rituximabanti-CD20 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)III
Treanda_ / bendamustinealkylating agent1st line metastatic Non-Hodgkin's Lymphoma (NHL)III
Trisenox_ / arsenic trioxidetaxane (a synthetic retinoid)Acute Myelogenous Leukemia (AML)III
lestaurtinib / CEP-701Flt-3 kinase inhibitorAcute Myelogenous Leukemia (AML)II
tamibarotene (+ arsenic trioxide) / INNO-507RAR alpha/beta agonistAcute Promyelocytic Leukemia (APL)IICytRx
CEP-32496BRAF kinase inhibitorBreast cancerII
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsFollicular Non-Hodgkin's Lymphoma (f-NHL)II
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsHodgkin's LymphomaII
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMyelodysplastic Syndrome (MDS)II
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMyelofibrosisII
lestaurtinib / CEP-701Flt-3 kinase inhibitorMyeloproliferative disordersII
tamibarotene / INNO-507RAR alpha/beta agonistNon Small Cell Lung Cancer (NSCLC)IICytRx
CEP-9722PARP inhibitorNon Small Cell Lung Cancer (NSCLC)II
CT-011PD-1 inhibitorVarious cancer typesIICuretech Ltd.
Quinamed_ / amonafide dihydrochloridetopoisomerase II inhibitorBreast cancerII
Quinamed_ / amonafide dihydrochloridetopoisomerase II inhibitorOvarian cancerII
Quinamed_ / amonafide dihydrochloridetopoisomerase II inhibitorProstate cancerII
Synribo_ / omacetaxine mepesuccinateprotein synthesis inhibitorAcute Myelogenous Leukemia (AML)II
Synribo_ / omacetaxine mepesuccinateprotein synthesis inhibitorMyelodysplastic Syndrome (MDS)II
Treanda_ (+ Rituxan_) / bendamustinealkylating agentMantle Cell Lymphoma (MCL)II
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteins1st line metastatic Small Cell Lung Cancer (SCLC)I
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsAcute Myelogenous Leukemia (AML)I
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMantle Cell Lymphoma (MCL)I
CEP-18770proteasome inhibitorMultiple MyelomaI
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMyelodysplastic Syndrome (MDS)I
CEP-11981VEGF-R/Tie-2 kinase inhibitorVarious cancer typesI
CEP-37440ALK/FAK kinase inhibitorVarious cancer typesI
CEP-9722PARP inhibitorVarious cancer typesI
Treanda_ (+ Velcade_) / bendamustinealkylating agentMultiple MyelomaI
CXS-299cell cycle inhibitorVarious cancer typesPreclinical
CEP-32496B-RAF kinase inhibitorVarious cancer typesPreclinicalChampions Biotechnology

View additional information on product candidates here »

Source


http://www.tevapharm.com/

Recent News Headlines

Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States

3/16/2017 05:05 pm

[Business Wire] - Teva Pharmaceutical Industries Ltd. today announced the launch of the Authorized Generic of Minastrin® 24 Fe1 1 mg/20 mcg in the U.S.

Teva to Present at the Barclays Global Annual Healthcare Conference

3/13/2017 03:00 pm

[Business Wire] - Teva Pharmaceutical Industries Ltd. will host a live audio webcast at the Barclays Global Healthcare Conference in Miami, Florida.